Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | ACACB | O00763 | 4/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25531115 | 1.00 | SIGMAR1 (0.40) | SIGMAR1EBPTP53TSHRTRPV1 | |
| SCHEMBL25531126 | 0.92 | SIGMAR1 (0.42) | SIGMAR1EBPTP53TSHRTRPV1 | |
| SCHEMBL25541883 | 0.85 | TP53 (0.39) | SIGMAR1EBPTP53TSHRTRPV1 | |
| SCHEMBL25531098 | 0.85 | TP53 (0.39) | SIGMAR1EBPTP53TSHRTRPV1 | |
| SCHEMBL25531116 | 0.84 | SIGMAR1 (0.39) | SIGMAR1EBPTP53TSHRTRPV1 | |
| SCHEMBL25541902 | 0.82 | TP53 (0.41) | SIGMAR1EBPTP53TSHRTRPV1 | |
| SCHEMBL25531101 | 0.81 | TP53 (0.40) | SIGMAR1EBPTP53TSHRTRPV1 | |
| SCHEMBL25541868 | 0.80 | TP53 (0.39) | SIGMAR1EBPTP53TSHRTRPV1 | |
| SCHEMBL25531039 | 0.77 | HRH3 (0.44) | SIGMAR1TRPV1HDAC3HDAC8HDAC6 | |
| SCHEMBL25531104 | 0.74 | SIGMAR1 (0.41) | SIGMAR1EBPTP53TSHRACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | SIGMAR1 1380/4885EBP 1039/4885TP53 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.